Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value-Based Care
Aetna’s Value-Based Process Improvement for the Survival of Community Oncology
By
Caroline Helwick
Economics & Value
,
Value-Based Care
May 2013, Vol 4, No 4
Hollywood, FL—Community oncology will not survive in the absence of novel management strategies and process improvements, according to Michael Kolodziej, MD, FACP, National Medical Director of Oncology Solutions, who offered his insights at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article
WellPoint’s Perspective on Value-Based Cancer Care for Today and Tomorrow
By
Caroline Helwick
Economics & Value
,
Value-Based Care
May 2013, Vol 4, No 4
Read Article
A Call for Transparency in Drug Pricing
Value-Based Care
,
VBCC Perspectives
January 2013, Vol 4, No 1
In the December 2012 issue of
Value-Based Cancer Care
(
VBCC
), several Editorial Board members addressed the recent events surrounding the cost of cancer drugs and the reduction of the price of ziv-aflibercept (Zaltrap).
VBCC
continued this discussion with Al B. Benson III, MD, FACP, FASCO.
Read Article
How Will We Pay for Cancer Treatment?
By
Ted Okon, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
With the fanfare of a New York Times Op-Ed piece by Peter B. Bach, MD, and colleagues, the announcement was made that Memorial Sloan-Kettering Cancer Center (MSKCC) would exclude the new colorectal cancer drug ziv-aflibercept (Zaltrap) from its formulary.
Read Article
Payers’ Support of Clinical Decisions Allows Providers to Choose Most Effective, Cost-Saving Therapies
By
Ira Klein, MD, MBA, FACP
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
The cost of cancer care is staggering. Global sales of cancer drugs alone are forecast to grow at a rate of 12% to 15% annually, reaching $75 billion to $80 billion by the end of this year, according to IMS Health.
Read Article
We Must Incorporate Value into Our Decision-Making Process
By
John L. Marshall, MD
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
We should all read with great interest the New York Times opinion piece by Peter B. Bach, MD, and colleagues from Memorial Sloan-Kettering Cancer Center on their rationale for not including ziv-aflibercept (Zaltrap) in its formulary for patients with metastatic or advanced colorectal cancer.
Read Article
Can Value-Based Cancer Care Address the Challenges Faced by Specialty Pharmacies in Oncology?
By
Atheer A. Kaddis, PharmD
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
March 2012, Vol 3, No 2
Specialty pharmacies are facing specific challenges in the ways they interact with payers, providers, and even with the pharmaceutical industry in relation to access and delivery of cancer drugs.
Read Article
The Promise of Molecular Profiling
By
Caroline Helwick
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
February 2012, Vol 3, No 1
At the 2012 Gastrointestinal Cancers Symposium, Value-Based Cancer Care (VBCC) asked Al B. Benson, III, MD, FACP, Professor of Medicine, Associate Director for Clinical Investigations, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Immediate Past President, ACCC, and editorial board member of VBCC, to discuss the growing importance of molecular profiling in cancer care.
Read Article
A New Paradigm of Value-Based Cancer Care: The NCCCP
By
Mark J. Krasna, MD
Cancer Care
,
Economics & Value
,
Value-Based Care
December 2011, Vol 2, No 7
Read Article
Clinical and Economic Impact of Multiple Myeloma
By
Matthew Mitchell, PharmD, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
December 2011, Vol 2, No 7
The clinical and economic impact of multiple myeloma is tremendous. With the onset of novel therapies used in multiple myeloma, as well as the release of new data demonstrating progression-free survival and overall survival, therapy used in multiple myeloma is now on the radar for payers, despite the relatively low incidence of the disease.
Read Article
Page 10 of 12
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma